Actively Recruiting
Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS
Led by University Hospital, Basel, Switzerland · Updated on 2025-12-04
10
Participants Needed
1
Research Sites
424 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study examines the application of expanded natural killer cells (NK cells) following haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) for AML or MDS. Haplo-HSCT is a preferred treatment option for patients with AML or MDS without a HLA-matched donor. With administration of cyclophosphamide post-transplant , the safety of the procedure is similar to a HSCT from a HLA-identical donor. Relapse of AML/MDS represents a serious problem following haplo-HSCT. NK cells are immune cells able to destroy tumor cells. Their potency has been established particularly in the setting of a haplo-HSCT. In the current study, study participants undergoing haplo-HSCT will receive expanded NK cells from their respective stem-cell donors following haplo-HSCT. The primary goal of the study is to establish the safety and feasibility of this approach. In addition, the activity of the NK cells will be examined.
CONDITIONS
Official Title
Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient older than 18 years
- No available HLA-matched related or unrelated donor
- Diagnosis of AML or MDS-EB with indication for haplo-HSCT
- Adequate organ function and no contraindications to haplo-HSCT as judged by transplant physicians
- Available related haploidentical donor
- Written informed consent from patient
- Donor older than 18 years, haploidentical parent, sibling, or other relative
- Donor suitable for cell donation and apheresis according to standard criteria
- Written informed consent from donor
You will not qualify if you...
- Diagnosis of acute promyelocytic leukemia (APL)
- Presence of relevant donor-specific anti-HLA antibodies
- Pregnancy in the patient
- Need for immunosuppression other than GvHD prophylaxis
- Pregnancy in the donor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Basel
Basel, Switzerland, 4031
Actively Recruiting
Research Team
M
Matyas Ecsedi, MD-PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here